VolitionRx Limited (VNRX) 10-Q 11 May 21 2021 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2021	May 06, 2021
Cover [Abstract]
Entity Registrant Name	VOLITIONRX LTD
Entity Central Index Key	0000093314
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Mar. 31, 2021
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2021
Entity Common Stock Shares Outstanding		52,892,713
Document Quarterly Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Current Assets
Cash and cash equivalents	$ 33,061,711	$ 19,444,737
Accounts receivable	14,238	7,118
Prepaid expenses	1,095,971	303,178
Other current assets	496,902	576,660
Total Current Assets	34,668,822	20,331,693
Property and equipment, net	5,249,398	5,171,134
Operating lease right-of-use assets	303,548	326,085
Intangible assets, net	288,003	321,641
Total Assets	40,509,771	26,150,553
Current Liabilities
Accounts payable	1,463,963	1,539,547
Accrued liabilities	3,365,696	3,491,740
Management and directors' fees payable	39,484	55,174
Current portion of long-term debt	840,556	841,319
Current portion of finance lease liabilities	56,941	59,930
Current portion of operating lease liabilities	167,364	179,624
Current portion of grant repayable	66,475	69,218
Total Current Liabilities	6,000,479	6,236,552
Long-term debt, net of current portion	2,390,687	2,606,885
Finance lease liabilities, net of current portion	564,484	601,967
Operating lease liabilities, net of current portion	142,015	151,828
Grant repayable, net of current portion	249,313	259,603
Total Liabilities	9,346,978	9,856,835
STOCKHOLDERS' EQUITY
Common Stock Authorized: 100,000,000 shares of common stock, at $0.001 par value Issued and outstanding: 52,871,001 shares and 48,607,017 shares, respectively	52,871	48,607
Additional paid-in capital	147,382,487	126,526,239
Accumulated other comprehensive income	74,155	(59,978)
Accumulated deficit	(116,290,117)	(110,173,971)
Total VolitionRx Limited Stockholders' Equity	31,219,396	16,340,897
Non-controlling interest	(56,603)	(47,179)
Total Stockholders' Equity	31,162,793	16,293,718
Total Liabilities and Stockholders' Equity	$ 40,509,771	$ 26,150,553

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
STOCKHOLDERS' EQUITY
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares par value	$ 0.001	$ 0.001
Common stock, shares issued	52,871,001	48,607,017
Common stock, shares outstanding	52,871,001	48,607,017

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenues
Royalty	$ 0	$ 240
Product	25,530	304
Total Revenues	25,530	544
Operating Expenses
Research and development	3,873,079	3,894,966
General and administrative	1,810,160	1,703,522
Sales and marketing	427,401	273,954
Total Operating Expenses	6,110,640	5,872,442
Operating Loss	(6,085,110)	(5,871,898)
Other Income (Expenses)
Grant income	0	7,924
Interest income	1,721	38,414
Interest expense	(42,181)	(33,779)
Total Other Income (Expenses)	(40,460)	12,559
Net Loss	(6,125,570)	(5,859,339)
Net Loss attributable to Non-Controlling Interest	9,424	9,567
Net Loss attributable to VolitionRx Limited Stockholders	(6,116,146)	(5,849,772)
Other Comprehensive Income (Loss)
Foreign currency translation adjustments	134,133	373,926
Net Comprehensive Loss	$ (5,991,437)	$ (5,485,413)
Net Loss Per Share - Basic and Diluted	$ (0.12)	$ (0.14)
Weighted Average Shares Outstanding
- Basic and Diluted	50,928,742	41,197,125

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders Equity (Unaudited) - USD ($)	Total	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Non Controlling Interest [Member]	Common stock [Member]
Balance, shares at Dec. 31, 2019						41,125,303
Balance, amount at Dec. 31, 2019	$ 14,198,566	$ 103,853,627	$ 125,670	$ (89,821,856)	$ 0	$ 41,125
Common stock issued for Director compensation in Volition Germany, shares						73,263
Common stock issued for Director compensation in Volition Germany, amount	333,969	333,896	0	0	0	$ 73
Common stock issued in exercise of stock options, shares						19,430
Common stock issued in exercise of stock options, amount	0	(20)	0	0	0	$ 20
Common stock repurchase and retirement, shares						(11,364)
Common stock repurchase and retirement, amount	(54,434)	(54,423)	0	0	0	$ (11)
Stock-based compensation	192,669	192,669	0	0	0	0
Foreign currency translation	373,926	0	373,926	0	0	0
Net loss for the period	(5,859,339)	0	0	(5,849,772)	(9,567)	$ 0
Balance, shares at Mar. 31, 2020						41,206,632
Balance, amount at Mar. 31, 2020	9,185,357	104,325,749	499,596	(95,671,628)	(9,567)	$ 41,207
Balance, shares at Dec. 31, 2020						48,607,017
Balance, amount at Dec. 31, 2020	16,293,718	126,526,239	(59,978)	(110,173,971)	(47,179)	$ 48,607
Stock-based compensation	555,342	555,342	0	0	0	0
Foreign currency translation	134,133	0	134,133	0	0	0
Net loss for the period	(6,125,570)	0	0	(6,116,146)	(9,424)	$ 0
Common stock issued for cash, shares						4,183,533
Common stock issued for cash, amount	20,328,928	20,324,744	0	0	0	$ 4,184
Common stock issued for cashless exercise of stock options and settlement of RSU's, shares						80,451
Common stock issued for cashless exercise of stock options and settlement of RSU's, amount	0	(80)	0	0	0	$ 80
Tax withholdings paid related to stock-based compensation	(23,758)	(23,758)	0	0	0	$ 0
Balance, shares at Mar. 31, 2021						52,871,001
Balance, amount at Mar. 31, 2021	$ 31,162,793	$ 147,382,487	$ 74,155	$ (116,290,117)	$ (56,603)	$ 52,871

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating Activities
Net loss	$ (6,125,570)	$ (5,859,339)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	227,342	180,188
Amortization of operating lease right-of-use assets	50,046	63,025
Stock-based compensation	555,342	192,669
Common stock issued for Director compensation in Volition Germany	0	333,969
Changes in operating assets and liabilities:
Prepaid expenses	(792,793)	(485,529)
Accounts receivable	(14,238)	(242)
Other current assets	86,907	(55,182)
Accounts payable and accrued liabilities	(87,002)	859,478
Management and directors' fees payable	(15,690)	33,681
Right-of-use assets operating leases liabilities	(49,485)	(61,614)
Net Cash Used In Operating Activities	(6,165,141)	(4,798,896)
Investing Activities:
Purchases of property and equipment	(483,940)	(330,691)
Net Cash Used In Investing Activities	(483,940)	(330,691)
Financing Activities:
Net proceeds from issuances of common shares	20,328,928	0
Tax withholdings paid related to stock-based compensation	(23,758)	0
Common stock repurchased	0	(54,434)
Proceeds from grants repayable	0	3,802
Proceeds from long-term debt	79,590	0
Payments on long-term debt	(161,727)	(115,884)
Payments on finance lease obligations	(14,722)	(35,575)
Net Cash Provided By (Used In) Financing Activities	20,208,311	(202,091)
Effect of foreign exchange on cash	57,744	335,727
Net Change in Cash	13,616,974	(4,995,951)
Cash and cash equivalents - Beginning of Period	19,444,737	16,966,168
Cash and cash equivalents - End of Period	33,061,711	11,970,217
Supplemental Disclosures of Cash Flow Information:
Interest paid	42,181	33,779
Non-Cash Financing Activities:
Common stock issued on cashless exercises of stock options	80	20
Offering costs from issuance of common stock	$ 119,029	$ 0

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Basis of Presentation and Summary of Significant Accounting Policies
Note 1 - Basis of Presentation and Summary of Significant Accounting Policies	Basis of Presentation The interim consolidated financial statements of VolitionRx Limited (the “Company”, "VolitionRx," "we" or "us") for the three months ended March 31, 2021 and March 31, 2020, respectively, are not audited. Our consolidated financial statements are prepared in accordance with the requirements for unaudited interim periods and, consequently, do not include all disclosures required to be made in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). In the opinion of our management, the accompanying consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of our financial position as of March 31, 2021, and our results of operations and cash flows for the periods ended March 31, 2021 and March 31, 2020, respectively. The results of operations for the periods ended March 31, 2021 and March 31, 2020, respectively, are not necessarily indicative of the results for a full-year period. These interim consolidated financial statements should be read in conjunction with the financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the Securities and Exchange Commission (the "SEC") on March 22, 2021. U se of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company also regularly evaluates estimates and assumptions related to deferred income tax asset valuation allowances, useful lives of property and equipment and intangible assets, borrowing rate used in operating lease right-of-use asset and liability valuations, impairment analysis of intangible assets, and valuations of stock-based compensation. Th e Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations could be affected. P rinciples of Consolidation The accompanying condensed consolidated financial statements for the period ended March 31, 2021 include the accounts of the Company and its subsidiaries. The Company has one wholly-owned subsidiary, Singapore Volition Pte. Limited (“Singapore Volition”). Singapore Volition has one wholly-owned subsidiary, Belgian Volition SRL (“Belgian Volition”). Belgian Volition has four subsidiaries, Volition Diagnostics UK Limited (“Volition Diagnostics”), Volition America, Inc. (“Volition America”), Volition Germany GmbH (“Volition Germany”), and its one majority-owned subsidiary Volition Veterinary Diagnostics Development LLC (“Volition Vet”). See Note 8(f) for more information regarding Volition Vet and Volition Germany. All intercompany balances and transactions have been eliminated in consolidation. Cash and Cash Equivalents For the purposes of the statements of cash flows, the Company considers interest bearing deposits with original maturity dates of three months or less to be cash equivalents. The Company invests excess cash from its operating cash accounts in overnight investments and reflects these amounts in cash and cash equivalents in the condensed consolidated balance sheets at fair value using quoted prices in active markets for identical assets. As of March 31, 2021, cash and cash equivalents totaled approximately $33.1 million, of which $20.2 million was held in an overnight money market account. Accounts Receivables Trade accounts receivable are stated at the amount the Company expects to collect. Due to the nature of the accounts receivable balance, the Company believes the risk of doubtful accounts is minimal and therefore no allowance is recorded. If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, additional allowances would be required. The Company may provide for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. Balances that remain outstanding after the Company has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable. As of March 31, 2021, the accounts receivable balance was $14,238 and the allowance for doubtful debts was $nil. Revenue Recognition The Company adopted Accounting Standards Codification (“ASC”)606, “ Revenue from Contracts with Customers,” The Company generates product revenues from the sale of its Nu.Q ® Revenues, and their respective treatment for financial reporting purposes under ASC 606, are as follows: Royalty The Company receives royalty revenues on the net sales recognized during the period in which the revenue is earned, and the amount is determinable from the licensee. These are presented in “Royalty” in the consolidated statements of operations and comprehensive loss. The Company does not have future performance obligations under this revenue stream. In accordance with ASC 606, the Company records these revenues based on estimates of the net sales that occurred during the relevant period from the licensee. The relevant period estimates of these royalties are based on preliminary gross sales data provided by Active Motif and analysis of historical gross-to-net adjustments. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known. Product The Company includes revenue from product sales recognized during the period in which goods are shipped to third parties, and the amount is deemed collectable from the third parties. These are presented in “Product” in the consolidated statements of operations and comprehensive loss. Services The Company includes revenue recognized from laboratory services performed in the Company’s laboratory on behalf of third parties in “Services” in the consolidated statements of operations and comprehensive loss. For each development and/or commercialization agreement that results in revenues, the Company identifies all performance obligations, aside from those that are immaterial, which may include a license to intellectual property and know-how, development activities and/or transition activities. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company’s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required. B asic and Diluted Net Loss Per Share The Company computes net loss per share in accordance with ASC 260, “Earnings Per Share,” Reclassification Certain amounts presented in previously issued financial statements have been reclassified to be consistent with the current period presentation. The Company has reclassified the prior period comparative amounts in the statement of stockholders’ equity and cash flows to be consistent with the current year classification. Recent Accounting Pronouncements The Company has implemented all new accounting pronouncements that are in effect. The Company does not believe there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations. COVID-19 Pandemic Impact On March 11, 2020, the World Health Organization designated the outbreak of the novel strain of coronavirus known as COVID-19 as a global pandemic. Governments and businesses around the world have taken unprecedented actions to mitigate the spread of COVID-19, including, but not limited to, implementing shelter-in-place orders, significant restrictions on travel, as well as restrictions and guidelines that prohibit many employees from going to work. Uncertainty with respect to the economic impacts of the pandemic has introduced significant volatility in the financial markets. The Company did not observe significant impacts on its business or results of operations for the three months ended March 31, 2021 and March 31, 2020 due to the global emergence of COVID-19. While the extent to which COVID-19 impacts the Company’s future results will depend on future developments, the pandemic and associated economic impacts could result in a material impact to the Company’s future financial condition, results of operations and cash flows .

Going Concern

Going Concern	3 Months Ended
	Mar. 31, 2021
Going Concern
Note 2 - Going Concern	Th e Company's condensed consolidated financial statements are p repared using U.S. GAAP applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has incurred losses since inception of $116.3 million , has negative cash flows from operations, and has minimal revenues, which creates substantial doubt about its ability to continue as a going concern for a period of at least one year from the date of issuance of these condensed consolidated financial statements. Th e future of the Company as an operating business will depend on its ability to obtain sufficient capital contributions, financing and/or to generate revenues as may be required to sustain its operations. Management plans to address the above as needed by (a) securing additional grant funds, (b) obtaining additional financing through debt or equity transactions, (c) granting licenses to third parties in exchange for specified up-front and/or back-end payments and (d) developing and commercializing its products on an accelerated timeline. Management continues to exercise tight cost controls to conserve cash. Th e ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually attain profitable operations. The accompanying condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced to cease operations.

Property and Equipment

Property and Equipment	3 Months Ended
	Mar. 31, 2021
Property and Equipment
Note 3 - Property and Equipment	The Company’s property and equipment consisted of the following amounts as of March 31, 2021 and December 31, 2020: March 31, 2021 Accumulated Net Carrying Cost Depreciation Value Useful Life $ $ $ Computer hardware and software 3 years 552,493 426,996 125,497 Laboratory equipment 5 years 2,865,730 1,139,320 1,726,410 Office furniture and equipment 5 years 280,690 177,367 103,323 Buildings 30 years 2,270,508 218,222 2,052,286 Building improvements 5-15 years 1,298,124 199,101 1,099,023 Land Not amortized 142,859 - 142,859 7,410,404 2,161,006 5,249,398 December 31, 2020 Accumulated Net Carrying Cost Depreciation Value Useful Life $ $ $ Computer hardware and software 3 years 550,254 412,805 137,449 Laboratory equipment 5 years 2,586,997 1,060,153 1,526,844 Office furniture and equipment 5 years 271,656 171,247 100,409 Buildings 30 years 2,366,236 207,111 2,159,125 Building improvements 5-15 years 1,285,383 184,813 1,100,570 Land Not amortized 146,737 - 146,737 7,207,263 2,036,129 5,171,134 During the three month periods ended March 31, 2021 and March 31, 2020, the Company recognized $204,049 and $158,768, respectively, in depreciation expense.

Intangible Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2021
Intangible Assets
Note 4 - Intangible Assets	The Company’s intangible assets consist of patents, mainly acquired in the acquisition of Belgian Volition. The patents are being amortized over the assets’ estimated useful lives, which range from 8 to 20 years. March 31, 2021 Accumulated Net Carrying Cost Amortization Value $ $ $ Patents 1,210,241 922,238 288,003 December 31, 2020 Accumulated Net Carrying Cost Amortization Value $ $ $ Patents 1,256,064 934,423 321,641 During the three month periods ended March 31, 2021 and March 31, 2020, the Company recognized $23,293 and $21,420, respectively, in amortization expense. The Company amortizes the patents on a straight-line basis with terms ranging from 8 to 20 years. The annual estimated amortization schedule over the next five years is as follows: 2021 - remaining $ 68,261 2022 $ 91,015 2023 $ 91,015 2024 $ 37,712 2025 $ - Total Intangible Assets $ 288,003 The Company periodically reviews its long-lived assets to ensure that their carrying value does not exceed their fair market value. The Company carried out such a review in accordance with ASC 360 Topic “Property, Plant and Equipment”

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2021
Related Party Transactions
Note 5 - Related Party Transactions	See Note 6 for common stock issued to related parties and Note 7 for stock options, warrants and RSUs issued to related parties. The Company has agreements with related parties for the purchase of products and consultancy services which are accrued under management and directors’ fees payable (see condensed consolidated balance sheets).

Common Stock

Common Stock	3 Months Ended
	Mar. 31, 2021
Common Stock
Note 6 - Common Stock	As of March 31, 2021, the Company was authorized to issue 100 million shares of common stock par value $0.001 per share, of which 52,871,001 and 48,607,017 shares were issued and outstanding as of March 31, 2021 and December 31, 2020, respectively. Stock Option Exercises and RSU Settlements From January 13 , 2021 to March 19, 2021 , 7,634 stock options were exercised to purchase shares of common stock at $3.35 per share in cashless exercises that resulted in the issuance of 948 shares of common stock. On January 20, 2021, 5,000 RSU’s were exercised to purchase shares of common stock at $4.10 per share in a cashless exercise that resulted in the issuance of 3,000 shares of common stock. On February 2, 2021 , 20,000 stock options were exercised to purchase shares of common stock at $3.80 per share in a cashless exercise that resulted in the issuance of 6,181 shares of common stock. On February 8, 2021 , 100,000 stock options were exercised to purchase shares of common stock at $5.00 per share in a cashless exercise that resulted in the issuance of 19,446 shares of common stock. From February 8, 2021 to February 9, 2021, 100,000 stock options were exercised to purchase shares of common stock at $4.00 per share in cashless exercises that resulted in the issuance of 32,126 shares of common stock. On February 8, 2021 , 50,000 stock options were exercised to purchase shares of common stock at $3.25 per share in a cashless exercise that resulted in the issuance of 18,750 shares of common stock. Equity Capital Raise On February 10, 2021, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co. (the “Underwriter”) in connection with an underwritten public offering (the “Offering”) of 3,809,524 shares (the “Firm Shares”) of the Company’s common stock, $0.001 par value per share (“Common Stock”) pursuant to the Company’s shelf registration statement on Form S-3 (declared effective by the SEC on September 28, 2018, File No. 333-227248). The Underwriter purchased the Firm Shares from the Company at a price of $4.9533 per share on February 12, 2021. The net proceeds received by the Company for the sale and issuance of the Firm Shares were approximately $18.9 million. Under the terms of the Underwriting Agreement, the Company granted the Underwriter an option, exercisable for 30 days, to purchase up to an additional 571,428 shares of Common Stock (the “Option Shares”) at the same price per share as the Firm Shares which option was not exercised. Equity Distribution Agreements On November 10, 2020, the Company entered into an equity distribution agreement (the “2020 EDA”) with Cantor Fitzgerald & Co. (“Cantor”) and Oppenheimer & Co. Inc. (“Oppenheimer”), to sell shares of its common stock having an aggregate offering price of up to $25,000,000 from time-to-time, through an “at the market offering program” pursuant to the Company’s effective “shelf” registration statement on Form S-3 (File No. 333-227248) and related prospectuses, through Cantor and Oppenheimer each acting as the Company’s agent and/or principal . The Company is not obligated to sell any shares under the 2020 EDA. From inception through March 31, 2021, the Company raised aggregate net proceeds (net of broker’s commissions and fees) of $343,957 under the 2020 EDA through the sale of 65,400 shares of its common stock all of which occurred during the first quarter of 2021. On September 7, 2018, the Company entered into an equity distribution agreement (as amended, the “2018 EDA”) with Oppenheimer to sell shares of common stock having an aggregate offering price of up to $10.0 million from time-to-time, through an “at the market offering program” pursuant to the Company’s effective “shelf” registration statement on Form S-3 (File No 333-227248) and related prospectuses, through Oppenheimer acting as the Company’s agent and/or principal. During the first quarter of 2021, the Company raised aggregate net proceeds (net of broker’s commissions and fees) of approximately $1.2 million under the 2018 EDA through the sale of 308,609 shares of its common stock . From inception through March 31, 2021, t he Company raised aggregate net proceeds (net of broker’s commissions and fees) of approximately $9.7 million under the 2018 EDA through the sale of 2,539,606 shares of its common stock and fully utilized the availability under the 2018 EDA. No further sales will be made under the 2018 EDA.

StockBased Compensation

StockBased Compensation	3 Months Ended
	Mar. 31, 2021
StockBased Compensation
Note 7 - Stock-based Compensation	a ) Warrants The following table summarizes the changes in warrants outstanding of the Company during the three month period ended March 31, 2021: Number of Weighted Average Warrants Exercise Price ($) Outstanding at December 31, 2020 175,000 2.75 Granted 310,000 4.52 Outstanding at March 31, 2021 485,000 3.88 Exercisable at March 31, 2021 125,000 2.47 Effective January 1, 2021, the Company granted warrants to purchase 125,000 shares of common stock to a Company employee for services to the Company. These warrants vest on January 1, 2022 (subject to continued employment through such date) and expire on January 1, 2027, with an exercise price of $3.95 per share. The Company has calculated the estimated fair market value of these warrants at $242,877, using the Black-Scholes model and the following assumptions: term 3.5 years, stock price $3.95, exercise price $3.80, 74.53% volatility, 0.50% risk free rate, and no forfeiture rate. Effective February 1, 2021, the Company granted warrants to purchase 185,000 shares of common stock to a Company employee for services to the Company. These warrants vest on February 1, 2022 (subject to continued employment through such date) and expire on February 1, 2027, with an exercise price of $4.90 per share. The Company has calculated the estimated fair market value of these warrants at $459,352, using the Black-Scholes model and the following assumptions: term 3.5 years, stock price $4.90, exercise price $4.80, 75.03% volatility, 0.59% risk free rate, and no forfeiture rate . Below is a table summarizing the warrants issued and outstanding as of March 31, 2021, which have an aggregate weighted average remaining contractual life of 4.71 years. Weighted Average Remaining Proceeds to Number Number Exercise Contractual Company if Outstanding Exercisable Price ($) Life (Years) Exercised ($) 125,000 125,000 2.47 0.95 308,750 50,000 - 3.45 4.92 172,500 185,000 - 4.90 5.84 906,500 125,000 - 3.95 5.76 493,750 485,000 125,000 1,881,500 Stock-based compensation expense related to warrants of $148,364 and $27,205 was recorded in the three months ended March 31, 2021 and March 31, 2020, respectively. Total remaining unrecognized compensation cost related to non-vested warrants is $592,341 and is expected to be recognized over a period of 0.84 years. As of March 31, 2021, the total intrinsic value of warrants outstanding was $180,250. b) Options The following table summarizes the changes in options outstanding of the Company during the three month period ended March 31, 2021: Number of Weighted Average Options Exercise Price ($) Outstanding at December 31, 2020 4,278,619 3.88 Exercised (277,634 ) 4.19 Outstanding at March 31, 2021 4,000,985 3.99 Exercisable at March 31, 2021 3,170,985 4.09 Below is a table summarizing the options issued and outstanding as of March 31, 2021, all of which were issued pursuant to the 2011 Equity Incentive Plan (for option issuances prior to 2016) or the 2015 Stock Incentive Plan (for option issuances commencing in 2016)and which have an aggregate weighted average remaining contractual life of 2.75 years. As of March 31, 2021, an aggregate of 4,250,000 shares of common stock were authorized for issuance under the 2015 Stock Incentive Plan, of which 404,314 shares of common stock remained available for future issuance thereunder. Weighted Average Remaining Proceeds to Number Number Exercise Contractual Company if Outstanding Exercisable Price ($) Life (Years) Exercised ($) 635,000 635,000 3.25 3.87 2,063,750 2,717 2,717 3.35 0.12 9,102 10,000 - 3.40 5.67 34,000 820,000 - 3.60 5.04 2,952,000 1,682,837 1,682,837 4.00 1.56 6,731,348 15,268 15,268 4.35 0.90 66,416 89,163 89,163 4.38 2.82 390,534 50,000 50,000 4.80 1.76 240,000 696,000 696,000 5.00 1.99 3,480,000 4,000,985 3,170,985 15,967,150 Stock-based compensation expense related to stock options of $355,076 and $165,464 was recorded in the three months ended March 31, 2021 and March 31, 2020, respectively. Total remaining unrecognized compensation cost related to non-vested stock options is $71,854. As of March 31, 2021, the total intrinsic value of stock options outstanding was $489,118. c) Restricted Stock Units (RSUs) Below is a table summarizing the RSUs issued and outstanding as of March 31, 2021, all of which were issued pursuant to the 2015 Stock Incentive Plan. Number of RSUs Share Price ($) Outstanding at December 31, 2020 67,500 3.47 Granted 35,000 3.66 Vested (5,000 ) 4.10 Cancelled (15,000 ) 3.30 Outstanding at March 31, 2021 82,500 3.55 Effective January 1, 2021, the Company granted RSUs of 5,000 shares of common stock to a Company employee in exchange for services provided to the Company. These RSUs vested immediately, on January 1, 2021 and resulted in the issuance of 3,000 shares (the remaining 2,000 shares were withheld for taxes and returned as authorized shares under the 2015 Stock Incentive Plan) and total compensation expense of $19,450. Effective March 25, 2021, the Company granted aggregate RSUs of 30,000 shares of common stock to two non-executive directors in exchange for services provided to the Company. These RSUs vest over 2 years, with 50% vesting on each of March 25, 2022 and March 25, 2023 and will result in total compensation expense of $107,700. On March 25, 2021, 15,000 RSUs previously granted to a non-executive director were cancelled and returned as authorized shares under the 2015 Stock Incentive Plan upon the resignation of such director prior to vesting. Below is a table summarizing the RSUs issued and outstanding as of March 31, 2021 and which have an aggregate weighted average remaining contractual life of 0.88 years. Weighted Average Remaining Number Share Contractual Outstanding Price ($) Life (Years) 52,500 3.52 0.54 30,000 3.59 1.48 82,500 Stock-based compensation expense related to RSUs of $51,902 and $nil was recorded in the three months ended March 31, 2021 and March 31, 2020, respectively. Total remaining unrecognized compensation cost related to non-vested RSUs is $157,509. As of March 31, 2021, the total intrinsic value of the RSUs outstanding was $19,350.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies
Note 8 - Commitments and Contingencies	a) Finance Lease Obligations In 2016, the Company entered into a real estate finance lease with ING Asset Finance Belgium S.A. (“ING”) to purchase a property located in Belgium for €1.12 million, maturing in May 2031 with implicit interest of 2.62%. As of March 31, 2021, the balance payable was $612,599. In 2018, the Company entered into a capital lease with BNP Paribas leasing solutions to purchase a freezer for the Belgium facility for €25,000, maturing in January 2022 with implicit interest of 1.35%. The leased equipment is amortized on a straight-line basis over 5 years. As of March 31, 2021, the balance payable was $8,826. The following is a schedule showing the future minimum lease payments under finance leases by years and the present value of the minimum payments as of March 31, 2021. 2021 - remaining $ 54,872 2022 $ 64,640 2023 $ 63,165 2024 $ 63,163 2025 $ 63,163 Greater than 5 years $ 402,652 Total $ 711,655 Less: Amount representing interest $ (90,230) Present Value of Minimum Lease Payments $ 621,425 b) Operating Lease Right-of-Use Obligations As all the existing leases subject to the new lease standard ASC 842 (“Leases”) As of March 31, 2021, operating lease right-of-use assets and liabilities arising from operating leases were $303,548 and $309,379, respectively. During the three months ended March 31, 2021, cash paid for amounts included for the measurement of lease liabilities was $21,562 and the Company recorded operating lease expense of $21,488. The following is a schedule showing the future minimum lease payments under operating leases by years and the present value of the minimum payments as of March 31, 2021. 2021 - remaining $ 142,623 2022 $ 85,019 2023 $ 59,828 2024 $ 33,674 2025 $ 726 Total Operating Lease Obligations $ 321,870 Less: Amount representing interest $ (12,491) Present Value of Minimum Lease Payments $ 309,379 The Company’s office space leases are short-term and the Company has elected under the short-term recognition exemption not to recognize them on the balance sheet. During the three months ended March 31, 2021, $15,647 was recognized in short-term lease costs associated with office space leases. The annual payments remaining for short-term office leases were as follows: 2021 - remaining $ 19,232 Total Operating Lease Liabilities $ 19,232 c) Grants Repayable In 2010, the Company entered into an agreement with the Walloon Region government in Belgium for a colorectal cancer research grant for €1.05 million. Per the terms of the agreement, €314,406 of the grant is to be repaid, by installments over the period from June 30, 2014 to June 30, 2023. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 6% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €314,406 and the 6% royalty on revenue, is equal to twice the amount of funding received. As of March 31, 2021, the grant balance repayable was $102,645. In 2018, the Company entered into an agreement with the Walloon Region government in Belgium for a colorectal cancer research grant for €605,000. Per the terms of the agreement, €181,500 of the grant is to be repaid by installments over 12 years commencing in 2020. As of March 31, 2021, the total grant balance repayable was $315,788 and the payments remaining were as follows: 2021 - remaining $ 66,475 2022 $ 49,440 2023 $ 50,664 2024 $ 21,314 2025 $ 28,419 Greater than 5 years $ 99,476 Total Grants Repayable $ 315,788 d) Long-Term Debt In 2016, the Company entered into a 7-year loan agreement with Namur Invest for €440,000 with a fixed interest rate of 4.85%, maturing in December 2023. As of March 31, 2021, the principal balance payable was $238,568. In 2016, the Company entered into a 15-year loan agreement with ING for €270,000 with a fixed interest rate of 2.62%, maturing in December 2031. As of March 31, 2021, the principal balance payable was $240,838. In 2017, the Company entered into a 4-year loan agreement with Namur Invest for €350,000 with a fixed interest rate of 4.00%, maturing in June 2021. As of March 31, 2021, the principal balance payable was $31,302. In 2017, the Company entered into a 7-year loan agreement with SOFINEX for up to €1 million with a fixed interest rate of 4.50%, maturing in September 2024. As of March 31, 2021, €1 million has been drawn down under this agreement and the principal balance payable was $939,474. In 2018, the Company entered into a 4-year loan agreement with Namur Innovation and Growth for €500,000 with a fixed interest rate of 4.00%, maturing in June 2022. As of March 31, 2021, the principal balance payable was $219,184. In 2019, the Company entered into a 4-year loan agreement with Namur Innovation and Growth for €500,000 with a fixed interest rate of 4.80%, maturing in September 2024. As of March 31, 2021, the principal balance payable was $587,171. On October 13, 2020, the Company entered into a 10-year loan agreement with Namur Invest for a maximum of €830,000 with fixed interest rate of 4.00%, maturing March 2031. During the quarter ended March 31, 2021, the Company borrowed €65,453 under the loan agreement. As of March 31, 2021, the maximum of €830,000 had been drawn down under this agreement, representing a principal balance payable of $974,706. As of March 31, 2021, the total balance for long-term debt payable was $3,231,243 and the payments remaining were as follows: 2021 - remaining $ 754,622 2022 $ 772,491 2023 $ 671,892 2024 $ 522,858 2025 $ 144,427 Greater than 5 years $ 777,748 Total $ 3,644,038 Less: Amount representing interest $ (412,795) Total Long-Term Debt $ 3,231,243 e) Collaborative Agreement Obligations In 2016, the Company entered into a research co-operation agreement with DKFZ in Germany for a 5-year period for €400,000. As of March 31, 2021, $234,869 is still to be paid by the Company under this agreement. In 2018, the Company entered into a research collaboration agreement with the University of Taiwan for a 3-year period for a cost to the Company of up to $2.55 million payable over such period. As of March 31, 2021, $510,000 is still to be paid by the Company under this agreement. In 2019, the Company entered into a research collaboration agreement with the University of Taiwan for a 2-year period to collect a total of 1,200 samples for a cost to the Company of up to $320,000 payable over such period. As of March 31, 2021, $96,000 is still to be paid by the Company under this agreement. In 2019, the Company entered into a funded sponsored research agreement with the Texas A&M University (“TAMU”) in consideration for the license granted to the Company for a 5-year period for a cost to the Company of up to $400,000 payable over such period. As of March 31, 2021, $235,036 is still to be paid by the Company under this agreement. On September 16, 2020, the Company entered into a research agreement for the bioinformatic analysis of cell-free DNA fragments from whole-genome sequencing with the Hebrew University of Jerusalem for 6 months for a cost to the Company of €54,879. As of March 31, 2021, $21,482 is still to be paid by the Company under this agreement. As of March 31, 2021, the total amount to be paid for future research and collaboration commitments was approximately $1.10 million and the payments remaining were as follows: 2021 - remaining $ 982,387 2022 - 2025 $ 115,000 Total Collaborative Agreement Obligations $ 1,097,387 f) Other Commitments Volition Vet On October 25, 2019, the Company entered into an agreement with TAMU for provision of in kind services of personnel, animal samples and laboratory equipment in exchange for a non-controlling interest of 7.5% in Volition Vet with an additional 5%, vesting in a year from the date of the agreement, giving TAMU in aggregate, a 12.5% equity interest as of such date. As of March 31, 2021, TAMU has a 12.5 % equity interest in Volition Vet. Volition Germany On January 10, 2020, the Company, through its wholly-owned subsidiary Belgian Volition, acquired an epigenetic reagent company, Octamer GmbH (“Octamer”), based in Munich, Germany, and hired its founder for his expertise and knowledge to be passed to Company personnel. On March 9, 2020, Octamer was renamed to Volition Germany GmbH (or “Volition Germany”). Upon considering the definition of a business, as defined in ASC 805 “Business Combinations,” - The Company agreed to terms of the transaction on December 13, 2019 and closed on January 10, 2020. Pursuant to the transaction agreement, the Company purchased all outstanding shares of Octamer. In exchange, the Company agreed to issue 73,263 newly-issued restricted shares of Company common stock valued at $333,969 (based on the $4.56 per share volume weighted trading price for the five days prior to December 13, 2019), committed to pay approximately €350,000, subject to adjustments, and agreed to pay off certain Octamer expenses leading up to the agreement (representing net liabilities of $6,535). At closing, the Company issued 73,263 restricted shares of Company common stock, paid an adjusted amount of approximately $357,000 (€321,736) and recorded a holdback liability of $55,404 (€50,000). During the quarter ended March 31, 2021, an amount of €43,152 was paid in full settlement of the amount due. In connection with the transaction agreement, the Company also entered into a 2-year Managing Director’s agreement with the founder of Octamer to continue to manage Volition Germany for a payment of €288,000 payable in equal monthly installments over such 2-year period and a royalty agreement with the founder providing for the payment of royalties in the amount of 6% of net sales of Volition Germany’s nucleosomes as reagents to pharmaceutical companies for use in the development, manufacture and screening of molecules for use as therapeutic drugs for a period of 5 years post-closing. The Company recorded approximately $753,000 in compensation expense as a result of cash paid, holdback liability, stock issued and assumption of expenses. As of March 31, 2021,$126,829 is still to be paid by the Company under the Managing Director’s agreement and $229 is payable under the 6% royalty agreement. Volition America On November 3, 2020, the Company entered into a professional services master agreement with Diagnostic Oncology CRO, LLC to conduct a pivotal clinical trial and provide regulatory submission and reimbursement related services. Under the terms of the agreement Diagnostic Oncology CRO, LLC will provide ad hoc consulting assistance on a project-by-project basis related to the review and assessment of existing data and information to prepare recommended intended use claims and coverage/reimbursement plans to support the preparation of FDA pre-submissions, clinical trial protocol development and study administration, and potential 510k regulatory marketing submissions of the Company’s diagnostic tests, including those proposed for use as an adjunct diagnostic tool for common and aggressive forms of Non-Hodgkin’s Lymphoma. The initial projects contemplated by the agreement relating to Non-Hodgkin’s Lymphoma obligate the Company to pay in aggregate of up to $2.9 million over a period of 22 months. Such payment obligations are on a project-by-project basis as deliverables are executed and subject to certain terms and conditions. Additionally, the Company may terminate the agreement or any project with or without cause upon at least 30 days’ prior written notice. Unless earlier terminated, the term of the agreement is until December 31, 2025 or such later date as when all projects have been completed. As of March 31, 2021, $nil is payable by Company for services rendered under the agreement. g) Legal Proceedings There are no legal proceedings which the Company believes will have a material adverse effect on its financial position.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2021
Subsequent Events
Note 9 - Subsequent Events	On April 13, 2021, 20,625 RSUs were settled net of tax withholdings at $3.44 per share that resulted in the issuance of 16,087 shares of common stock. On April 13, 2021, 5,625 RSUs were settled at $3.44 per share that resulted in the issuance of 5,625 shares of common stock. Effective May 1, 2021, the Company granted RSUs of 150,000 shares of common stock to a Company employee in exchange for services provided to the Company. These RSUs vest as follows one-third after 12 months, one-third after 24 months, and the remaining one-third after 36 months and will result in total compensation expense of $496,500.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Basis of Presentation and Summary of Significant Accounting Policies (Policies)
Basis of Presentation	The interim consolidated financial statements of VolitionRx Limited (the “Company”, "VolitionRx," "we" or "us") for the three months ended March 31, 2021 and March 31, 2020, respectively, are not audited. Our consolidated financial statements are prepared in accordance with the requirements for unaudited interim periods and, consequently, do not include all disclosures required to be made in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). In the opinion of our management, the accompanying consolidated financial statements contain all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of our financial position as of March 31, 2021, and our results of operations and cash flows for the periods ended March 31, 2021 and March 31, 2020, respectively. The results of operations for the periods ended March 31, 2021 and March 31, 2020, respectively, are not necessarily indicative of the results for a full-year period. These interim consolidated financial statements should be read in conjunction with the financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020, which was filed with the Securities and Exchange Commission (the "SEC") on March 22, 2021.
Use of Estimates	The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company also regularly evaluates estimates and assumptions related to deferred income tax asset valuation allowances, useful lives of property and equipment and intangible assets, borrowing rate used in operating lease right-of-use asset and liability valuations, impairment analysis of intangible assets, and valuations of stock-based compensation. Th e Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations could be affected.
Principles of Consolidation	The accompanying condensed consolidated financial statements for the period ended March 31, 2021 include the accounts of the Company and its subsidiaries. The Company has one wholly-owned subsidiary, Singapore Volition Pte. Limited (“Singapore Volition”). Singapore Volition has one wholly-owned subsidiary, Belgian Volition SRL (“Belgian Volition”). Belgian Volition has four subsidiaries, Volition Diagnostics UK Limited (“Volition Diagnostics”), Volition America, Inc. (“Volition America”), Volition Germany GmbH (“Volition Germany”), and its one majority-owned subsidiary Volition Veterinary Diagnostics Development LLC (“Volition Vet”). See Note 8(f) for more information regarding Volition Vet and Volition Germany. All intercompany balances and transactions have been eliminated in consolidation.
Cash and Cash Equivalents	For the purposes of the statements of cash flows, the Company considers interest bearing deposits with original maturity dates of three months or less to be cash equivalents. The Company invests excess cash from its operating cash accounts in overnight investments and reflects these amounts in cash and cash equivalents in the condensed consolidated balance sheets at fair value using quoted prices in active markets for identical assets. As of March 31, 2021, cash and cash equivalents totaled approximately $33.1 million, of which $20.2 million was held in an overnight money market account.
Accounts Receivables	Trade accounts receivable are stated at the amount the Company expects to collect. Due to the nature of the accounts receivable balance, the Company believes the risk of doubtful accounts is minimal and therefore no allowance is recorded. If the financial condition of the Company’s customers were to deteriorate, adversely affecting their ability to make payments, additional allowances would be required. The Company may provide for estimated uncollectible amounts through a charge to earnings and a credit to a valuation allowance. Balances that remain outstanding after the Company has used reasonable collection efforts are written off through a charge to the valuation allowance and a credit to accounts receivable. As of March 31, 2021, the accounts receivable balance was $14,238 and the allowance for doubtful debts was $nil.
Revenue Recognition	The Company adopted Accounting Standards Codification (“ASC”)606, “ Revenue from Contracts with Customers,” The Company generates product revenues from the sale of its Nu.Q ® Revenues, and their respective treatment for financial reporting purposes under ASC 606, are as follows: Royalty The Company receives royalty revenues on the net sales recognized during the period in which the revenue is earned, and the amount is determinable from the licensee. These are presented in “Royalty” in the consolidated statements of operations and comprehensive loss. The Company does not have future performance obligations under this revenue stream. In accordance with ASC 606, the Company records these revenues based on estimates of the net sales that occurred during the relevant period from the licensee. The relevant period estimates of these royalties are based on preliminary gross sales data provided by Active Motif and analysis of historical gross-to-net adjustments. Differences between actual and estimated royalty revenues are adjusted for in the period in which they become known. Product The Company includes revenue from product sales recognized during the period in which goods are shipped to third parties, and the amount is deemed collectable from the third parties. These are presented in “Product” in the consolidated statements of operations and comprehensive loss. Services The Company includes revenue recognized from laboratory services performed in the Company’s laboratory on behalf of third parties in “Services” in the consolidated statements of operations and comprehensive loss. For each development and/or commercialization agreement that results in revenues, the Company identifies all performance obligations, aside from those that are immaterial, which may include a license to intellectual property and know-how, development activities and/or transition activities. In order to determine the transaction price, in addition to any upfront payment, the Company estimates the amount of variable consideration at the outset of the contract either utilizing the expected value or most likely amount method, depending on the facts and circumstances relative to the contract. The Company constrains (reduces) the estimates of variable consideration such that it is probable that a significant reversal of previously recognized revenue will not occur throughout the life of the contract. When determining if variable consideration should be constrained, management considers whether there are factors outside the Company’s control that could result in a significant reversal of revenue. In making these assessments, the Company considers the likelihood and magnitude of a potential reversal of revenue. These estimates are re-assessed each reporting period as required.
Basic and Diluted Net Loss Per Share	The Company computes net loss per share in accordance with ASC 260, “Earnings Per Share,”
Reclassification	Certain amounts presented in previously issued financial statements have been reclassified to be consistent with the current period presentation. The Company has reclassified the prior period comparative amounts in the statement of stockholders’ equity and cash flows to be consistent with the current year classification.
Recent Accounting Pronouncements	The Company has implemented all new accounting pronouncements that are in effect. The Company does not believe there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.
COVID-19 Pandemic Impact	On March 11, 2020, the World Health Organization designated the outbreak of the novel strain of coronavirus known as COVID-19 as a global pandemic. Governments and businesses around the world have taken unprecedented actions to mitigate the spread of COVID-19, including, but not limited to, implementing shelter-in-place orders, significant restrictions on travel, as well as restrictions and guidelines that prohibit many employees from going to work. Uncertainty with respect to the economic impacts of the pandemic has introduced significant volatility in the financial markets. The Company did not observe significant impacts on its business or results of operations for the three months ended March 31, 2021 and March 31, 2020 due to the global emergence of COVID-19. While the extent to which COVID-19 impacts the Company’s future results will depend on future developments, the pandemic and associated economic impacts could result in a material impact to the Company’s future financial condition, results of operations and cash flows .

Property and Equipment (Tables)

Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2021
Property and Equipment
Schedule of Property and Equipment	March 31, 2021 Accumulated Net Carrying Cost Depreciation Value Useful Life $ $ $ Computer hardware and software 3 years 552,493 426,996 125,497 Laboratory equipment 5 years 2,865,730 1,139,320 1,726,410 Office furniture and equipment 5 years 280,690 177,367 103,323 Buildings 30 years 2,270,508 218,222 2,052,286 Building improvements 5-15 years 1,298,124 199,101 1,099,023 Land Not amortized 142,859 - 142,859 7,410,404 2,161,006 5,249,398 December 31, 2020 Accumulated Net Carrying Cost Depreciation Value Useful Life $ $ $ Computer hardware and software 3 years 550,254 412,805 137,449 Laboratory equipment 5 years 2,586,997 1,060,153 1,526,844 Office furniture and equipment 5 years 271,656 171,247 100,409 Buildings 30 years 2,366,236 207,111 2,159,125 Building improvements 5-15 years 1,285,383 184,813 1,100,570 Land Not amortized 146,737 - 146,737 7,207,263 2,036,129 5,171,134

Intangible Assets (Tables)

Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2021
Intangible Assets
Schedule of Intangible Assets	March 31, 2021 Accumulated Net Carrying Cost Amortization Value $ $ $ Patents 1,210,241 922,238 288,003 December 31, 2020 Accumulated Net Carrying Cost Amortization Value $ $ $ Patents 1,256,064 934,423 321,641
Schedule of annual estimated amortization	2021 - remaining $ 68,261 2022 $ 91,015 2023 $ 91,015 2024 $ 37,712 2025 $ - Total Intangible Assets $ 288,003

StockBased Compensation (Tables

StockBased Compensation (Tables)	3 Months Ended
	Mar. 31, 2021
StockBased Compensation
Summary of changes in warrants outstanding	Number of Weighted Average Warrants Exercise Price ($) Outstanding at December 31, 2020 175,000 2.75 Granted 310,000 4.52 Outstanding at March 31, 2021 485,000 3.88 Exercisable at March 31, 2021 125,000 2.47
Summarizing the warrants issued and outstanding	Weighted Average Remaining Proceeds to Number Number Exercise Contractual Company if Outstanding Exercisable Price ($) Life (Years) Exercised ($) 125,000 125,000 2.47 0.95 308,750 50,000 - 3.45 4.92 172,500 185,000 - 4.90 5.84 906,500 125,000 - 3.95 5.76 493,750 485,000 125,000 1,881,500
Summarizes the changes in options outstanding	Number of Weighted Average Options Exercise Price ($) Outstanding at December 31, 2020 4,278,619 3.88 Exercised (277,634 ) 4.19 Outstanding at March 31, 2021 4,000,985 3.99 Exercisable at March 31, 2021 3,170,985 4.09
Summarizing the options issued and outstanding	Weighted Average Remaining Proceeds to Number Number Exercise Contractual Company if Outstanding Exercisable Price ($) Life (Years) Exercised ($) 635,000 635,000 3.25 3.87 2,063,750 2,717 2,717 3.35 0.12 9,102 10,000 - 3.40 5.67 34,000 820,000 - 3.60 5.04 2,952,000 1,682,837 1,682,837 4.00 1.56 6,731,348 15,268 15,268 4.35 0.90 66,416 89,163 89,163 4.38 2.82 390,534 50,000 50,000 4.80 1.76 240,000 696,000 696,000 5.00 1.99 3,480,000 4,000,985 3,170,985 15,967,150
Summarizing the RSUs issued and outstanding	Number of RSUs Share Price ($) Outstanding at December 31, 2020 67,500 3.47 Granted 35,000 3.66 Vested (5,000 ) 4.10 Cancelled (15,000 ) 3.30 Outstanding at March 31, 2021 82,500 3.55
Summarizing the RSUs issued and outstanding maturity life	Weighted Average Remaining Number Share Contractual Outstanding Price ($) Life (Years) 52,500 3.52 0.54 30,000 3.59 1.48 82,500

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2021
Commitments and Contingencies
Schedule of future minimum lease payments under financing leases	2021 - remaining $ 54,872 2022 $ 64,640 2023 $ 63,165 2024 $ 63,163 2025 $ 63,163 Greater than 5 years $ 402,652 Total $ 711,655 Less: Amount representing interest $ (90,230 ) Present Value of Minimum Lease Payments $ 621,425
Schedule of future minimum lease payments under operating leases	2021 - remaining $ 142,623 2022 $ 85,019 2023 $ 59,828 2024 $ 33,674 2025 $ 726 Total Operating Lease Obligations $ 321,870 Less: Amount representing interest $ (12,491 ) Present Value of Minimum Lease Payments $ 309,379
Schedule of recognized in short-term lease costs	2021 - remaining $ 19,232 Total Operating Lease Liabilities $ 19,232
Schedule of Grants Repayable	2021 - remaining $ 66,475 2022 $ 49,440 2023 $ 50,664 2024 $ 21,314 2025 $ 28,419 Greater than 5 years $ 99,476 Total Grants Repayable $ 315,788
Schedule of long-term debt payable	2021 - remaining $ 754,622 2022 $ 772,491 2023 $ 671,892 2024 $ 522,858 2025 $ 144,427 Greater than 5 years $ 777,748 Total $ 3,644,038 Less: Amount representing interest $ (412,795 ) Total Long-Term Debt $ 3,231,243
Schedule of annual payments of collaborative cgreement obligations	2021 - remaining $ 982,387 2022 - 2025 $ 115,000 Total Collaborative Agreement Obligations $ 1,097,387

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Basis of Presentation and Summary of Significant Accounting Policies (Policies)
Cash and cash equivalents	$ 33,100,000
Cash and cash equivalents money market account	20,200,000
Accounts receivable	14,238	$ 7,118
Allowance for doubtful Debts	$ 0
Potentially dilutive securities excluded from the computation of EPS	4,568,485

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	3 Months Ended		114 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021
Going Concern
Net loss	$ (6,125,570)	$ (5,859,339)	$ (116,300,000)

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Cost	$ 7,410,404	$ 7,207,263
Accumulated Depreciation	2,161,006	2,036,129
Net Carrying Value	5,249,398	5,171,134
Land [Member]
Cost	142,859	146,737
Accumulated Depreciation	0	0
Net Carrying Value	$ 142,859	$ 146,737
Useful Life	0 years	0 years
Computer Hardware And Software [Member]
Cost	$ 552,493	$ 550,254
Accumulated Depreciation	426,996	412,805
Net Carrying Value	$ 125,497	$ 137,449
Useful Life	3 years	3 years
Laboratory Equipment [Member]
Cost	$ 2,865,730	$ 2,586,997
Accumulated Depreciation	1,139,320	1,060,153
Net Carrying Value	$ 1,726,410	$ 1,526,844
Useful Life	5 years	5 years
Office Furniture and Equipment [Member]
Cost	$ 280,690	$ 271,656
Accumulated Depreciation	177,367	171,247
Net Carrying Value	$ 103,323	$ 100,409
Useful Life	5 years	5 years
Buildings [Member]
Cost	$ 2,270,508	$ 2,366,236
Accumulated Depreciation	218,222	207,111
Net Carrying Value	$ 2,052,286	$ 2,159,125
Useful Life	30 years	30 years
Building Improvements [Member]
Cost	$ 1,298,124	$ 1,285,383
Accumulated Depreciation	199,101	184,813
Net Carrying Value	$ 1,099,023	$ 1,100,570
Building Improvements [Member] | Minimum [Member]
Useful Life	5 years	5 years
Building Improvements [Member] | Maximum [Member]
Useful Life	15 years	15 years

Property and Equipment (Detai_2

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Property and Equipment
Depreciation Expense	$ 204,049	$ 158,768

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020
Net Carrying Value		$ 288,003	$ 321,641
Patents [Member]
Net Carrying Value	$ 288,003		321,641
Cost	1,210,241		1,256,064
Accumulated Amortization	$ 922,238		$ 934,423

Intangible Assets (Details 1)

Intangible Assets (Details 1) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Intangible Assets
2021 - remaining	$ 68,261
2022	91,015
2023	91,015
2024	37,712
2025	0
Total Intangible Assets	$ 288,003	$ 321,641

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Amortization expense	$ 23,293	$ 21,420
Minimum [Member] | Patents And Intellectual Property [Member]
Amortization of long-lived asset on straight line basis	8 years
Maximum [Member] | Patents And Intellectual Property [Member]
Amortization of long-lived asset on straight line basis	20 years

Common Stock (Details Narrative

Common Stock (Details Narrative) - USD ($)	Feb. 10, 2021	Nov. 10, 2020	Sep. 07, 2018	Mar. 31, 2021	Mar. 31, 2021	Feb. 12, 2021	Jan. 01, 2021	Dec. 31, 2020
Common stock, shares authorized				100,000,000	100,000,000			100,000,000
Common stock, shares issued				52,871,001	52,871,001			48,607,017
Common stock, shares outstanding				52,871,001	52,871,001			48,607,017
Common stock, par value				$ 0.001	$ 0.001			$ 0.001
Common stock shares issuable upon exercise of warrants							5,000
February 8, 2021 To February 9, 2021 [Member] | Stock Option [Member]
Price per share				$ 4	$ 4
Common stock shares issuable upon exercise of warrants				100,000	100,000
Common stock, share issued upon cashless exercise				32,126
February 8, 2021 [Member] | Stock Option Two [Member]
Price per share				$ 3.25	$ 3.25
Common stock, share issued upon cashless exercise				18,750
Common stock shares issuable upon exercise of warrants				50,000	50,000
February 8, 2021 [Member] | Stock Option One [Member]
Price per share				$ 5	$ 5
Common stock, share issued upon cashless exercise				19,446
Common stock shares issuable upon exercise of warrants				100,000	100,000
Option [Member] | From January 13, 2021 to March 19, 2021 [Member]
Price per share				$ 3.35	$ 3.35
Common stock shares issuable upon exercise of warrants				7,634	7,634
Common stock, share issued upon cashless exercise				948
Option [Member] | On January 20, 2021 [Member]
Price per share				$ 4.10	$ 4.10
Common stock shares issuable upon exercise of warrants				5,000	5,000
Common stock, share issued upon cashless exercise				3,000
Option [Member] | On 2, February 2021 [Member]
Price per share				$ 3.80	$ 3.80
Common stock shares issuable upon exercise of warrants				20,000	20,000
Common stock, share issued upon cashless exercise				6,181
Equity Distribution Agreement [Member]
Aggeregate share of common stock offering price		$ 25,000,000	$ 10,000,000
Common stock shares sold			308,609	65,400
Net proceeds of common stock shares			$ 1,200,000		$ 343,957
Aggregate shares of common stock					2,539,606
Agreement fees					$ 9,700,000
Underwriting Agreement [Member]
Aggeregate share of common stock offering price	$ 3,809,524
Issuance of common stock	571,428
Proceeds from Issuance of common stock	$ 18,900,000
Price per share	$ 0.001
Purchase price per share						$ 4.9533

StockBased Compensation (Detail

StockBased Compensation (Details) - Warrants [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Number of warrants
Number of warrants Outstanding beginning balance	485,000	175,000
Number of warrants granted		310,000
Number of warrants outstanding ending balance	485,000	485,000
Number of Warrants Exercisable	125,000	0
Weighted Exercise Price
Weighted Average Exercise Price Outstanding balance	$ 3.88	$ 2.75
Weighted Average Exercise Price Granted		4.52
Weighted Average Exercise Price ending balance	3.88	$ 3.88
Weighted Average Exercise Price exercisable	$ 2.47

StockBased Compensation (Deta_2

StockBased Compensation (Details 1)	3 Months Ended
	Mar. 31, 2021USD ($)$ / sharesshares
Number Exercisable	125,000
Number Outstanding	485,000
Proceeds to Company if Exercised | $	$ 1,881,500
Weighted Average Remaining Contractual Life (Years)	4 years 8 months 16 days
Warrants [Member]
Number Exercisable	0
Number Outstanding	125,000
Proceeds to Company if Exercised | $	$ 493,750
Exercise Price | $ / shares	$ 3.95
Weighted Average Remaining Contractual Life (Years)	5 years 9 months 4 days
Warrant One [Member]
Number Exercisable	125,000
Number Outstanding	125,000
Proceeds to Company if Exercised | $	$ 308,750
Exercise Price | $ / shares	$ 2.47
Weighted Average Remaining Contractual Life (Years)	11 months 12 days
Warrant Two [Member]
Number Exercisable	0
Number Outstanding	50,000
Proceeds to Company if Exercised | $	$ 172,500
Exercise Price | $ / shares	$ 3.45
Weighted Average Remaining Contractual Life (Years)	4 years 11 months 1 day
Warrant Three [Member]
Number Exercisable	0
Number Outstanding	185,000
Proceeds to Company if Exercised | $	$ 906,500
Exercise Price | $ / shares	$ 4.90
Weighted Average Remaining Contractual Life (Years)	5 years 10 months 2 days

StockBased Compensation (Deta_3

StockBased Compensation (Details 2) - Stock Option Four [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Number of options
Number of options outstanding beginning balance	4,000,985	4,278,619
Exercised		(277,634)
Number of option outstanding ending balance	4,000,985	4,000,985
Number of options exercisable	3,170,985	0
Weighted Average Exercise Price
Weighted Average Exercise Price Outstanding balance	$ 3.99	$ 3.88
Weighted Average Exercise Price Exercised	0	4.19
Weighted Average Exercise Price ending balance	3.99	3.99
Weighted Average Exercise Price exercisable balance	$ 4.09	$ 0

StockBased Compensation (Deta_4

StockBased Compensation (Details 3)	3 Months Ended
	Mar. 31, 2021USD ($)$ / sharesshares
Number Outstanding, shares	4,000,985
Number Exercisable, shares	3,170,985
Proceeds to Company if Exercised | $	$ 15,967,150
Stock Option One [Member]
Number Outstanding, shares	635,000
Number Exercisable, shares	635,000
Proceeds to Company if Exercised | $	$ 2,063,750
Exercise Price | $ / shares	$ 3.25
Weighted Average Remaining Contractual Life(years)	3 years 10 months 13 days
Option Two [Member]
Number Outstanding, shares	2,717
Number Exercisable, shares	2,717
Proceeds to Company if Exercised | $	$ 9,102
Exercise Price | $ / shares	$ 3.35
Weighted Average Remaining Contractual Life(years)	1 month 13 days
Total Stock Option [Member]
Number Outstanding, shares	10,000
Proceeds to Company if Exercised | $	$ 34,000
Exercise Price | $ / shares	$ 3.40
Weighted Average Remaining Contractual Life(years)	5 years 8 months 1 day
Stock Option Four [Member]
Number Outstanding, shares	820,000
Number Exercisable, shares	0
Proceeds to Company if Exercised | $	$ 2,952,000
Exercise Price | $ / shares	$ 3.60
Weighted Average Remaining Contractual Life(years)	5 years 15 days
Option Six [Member]
Number Outstanding, shares	15,268
Number Exercisable, shares	15,268
Proceeds to Company if Exercised | $	$ 66,416
Exercise Price | $ / shares	$ 4.35
Weighted Average Remaining Contractual Life(years)	10 months 24 days
Option Seven [Member]
Number Outstanding, shares	1,682,837
Number Exercisable, shares	1,682,837
Proceeds to Company if Exercised | $	$ 6,731,348
Exercise Price | $ / shares	$ 4
Weighted Average Remaining Contractual Life(years)	1 year 6 months 22 days
Option Eight [Member]
Number Outstanding, shares	89,163
Number Exercisable, shares	89,163
Proceeds to Company if Exercised | $	$ 390,534
Exercise Price | $ / shares	$ 4.38
Weighted Average Remaining Contractual Life(years)	2 years 9 months 26 days
Option Nine [Member]
Number Outstanding, shares	50,000
Number Exercisable, shares	50,000
Proceeds to Company if Exercised | $	$ 240,000
Exercise Price | $ / shares	$ 4.80
Weighted Average Remaining Contractual Life(years)	1 year 9 months 4 days
Option Ten [Member]
Number Outstanding, shares	696,000
Number Exercisable, shares	696,000
Proceeds to Company if Exercised | $	$ 3,480,000
Exercise Price | $ / shares	$ 5
Weighted Average Remaining Contractual Life(years)	1 year 11 months 27 days

StockBased Compensation (Deta_5

StockBased Compensation (Details 4) - Stock Options [Member]	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Number of RSUs outstanding begining balance	67,500
Granted	35,000
Vested	(5,000)
Cancelled	(15,000)
Number of RSUs outstanding ending balance	82,500
Share price beginning balance | $ / shares	$ 3.47
Share price vested | $ / shares	4.10
Cancelled net | $ / shares	3.30
Share price ending balance | $ / shares	$ 3.55

StockBased Compensation (Deta_6

StockBased Compensation (Details 5)	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Total Stock Option [Member]
Number of stock Outstanding balance | shares	82,500
Share price | $ / shares	$ 0
Stock Option One [Member]
Number of stock Outstanding balance | shares	30,000
Share price | $ / shares	$ 3.59
Weighted average remaining contractual life (Years)	1 year 5 months 23 days
Stock Options Two [Member]
Number of stock Outstanding balance | shares	52,500
Share price | $ / shares	$ 3.52
Weighted average remaining contractual life (Years)	6 months 15 days

StockBased Compensation (Deta_7

StockBased Compensation (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
	Mar. 25, 2021	Mar. 31, 2021	Mar. 31, 2020	Feb. 01, 2021	Jan. 01, 2021
Stock compensation expenses		$ 148,364	$ 27,205
Compensation cost related to non-vested warrants		$ 592,341
Vesting term		10 months 2 days
Common stock shares issuable upon exercise of warrants					5,000
Restricted stock units description	The Company granted aggregate RSUs of 30,000 shares of common stock to two non-executive directors in exchange for services provided to the Company. These RSUs vest over 2 years, with 50% vesting on each of March 25, 2022 and March 25, 2023
Restricted stock units, shares	15,000
Aggregate weighted average remaining contractual life		4 years 8 months 16 days
Price per share				$ 4.90	$ 3.95
Intrinsic value		$ 180,250
Option [Member] | 2015 Equity Incentive Plan [Member]
Compensation cost related to non-vested warrants		$ 71,854
Aggregate weighted average remaining contractual life		2 years 8 months 30 days
Intrinsic value		$ 489,118
Stock-based compensation expense		$ 355,076	165,464
Common stock shares reserved for future issuance		404,314
Common stock, shares authorized		4,250,000
January 1, 2021 [Member]
Term		3 years 5 months 30 days
Stock price		$ 3.95
Volatility		74.53%
Exercise price		$ 3.80
Risk free rate		0.50%
Warrants to purchase, shares		125,000
Warrants to purchase, amount		$ 242,877
Common stock, share issued upon cashless exercise		3,000
Total Compensation expense	$ 107,700	$ 19,450
Expire description		These warrants vest on January 1, 2022 (subject to continued employment through such date) and expire on January 1, 2027, with an exercise price of $3.95 per share.
February 1, 2021 [Member]
Term		3 years 5 months 30 days
Stock price		$ 4.90
Volatility		75.03%
Exercise price		$ 4.80
Risk free rate		0.59%
Warrants to purchase, shares		185,000
Warrants to purchase, amount		$ 459,352
Expire description		These warrants vest on February 1, 2022 (subject to continued employment through such date) and expire on February 1, 2027, with an exercise price of $4.90 per share.
Restricted Stock Units [Member]
Stock compensation expenses		$ 51,902	$ 51,902
Compensation cost related to non-vested warrants		$ 157,509
Aggregate weighted average remaining contractual life		10 months 17 days
Intrinsic value		$ 19,350

Commitments and Contingencies_2

Commitments and Contingencies (Details) - Finance Lease Obligations [Member]	Mar. 31, 2021USD ($)
2021 - remaining	$ 54,872
2022	64,640
2023	63,165
2024	63,163
2025	63,163
Greater than 5 years	402,652
Total	711,655
Less: Amount representing interest	(90,230)
Present value of minimum lease payments	$ 621,425

Commitments and Contingencies_3

Commitments and Contingencies (Details 1)	Mar. 31, 2021USD ($)
Total Operating Lease Obligations	$ 19,232
Operating Lease Right of Use Obligations [Member]
2021 - remaining	142,623
2022	85,019
2023	59,828
2024	33,674
2025	726
Total Operating Lease Obligations	321,870
Less: Amount representing interest	(12,491)
Present value of minimum lease payments	$ 309,379

Commitments and Contingencies_4

Commitments and Contingencies (Details 2)	Mar. 31, 2021USD ($)
Commitments and Contingencies
2021 - remaining	$ 19,232
Total Operating Lease Liabilities	$ 19,232

Commitments and Contingencies_5

Commitments and Contingencies (Details 3) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
2021 - remaining	$ 66,475	$ 69,218
Grants Repayable [Member]
2021 - remaining	66,475
2022	49,440
2023	50,664
2024	21,314
2025	28,419
Greater than 5 years	99,476
Total Grants Repayable	$ 315,788

Commitments and Contingencies_6

Commitments and Contingencies (Details 4)	Mar. 31, 2021USD ($)
Commitments and Contingencies
2021 - remaining	$ 754,622
2022	772,491
2023	671,892
2024	522,858
2025	144,427
Greater than 5 years	777,748
Total	3,644,038
Less: Amount representing interest	(412,795)
Total Long-Term Debt	$ 3,231,243

Commitments and Contingencies_7

Commitments and Contingencies (Details 5)	Mar. 31, 2021USD ($)
Commitments and Contingencies
2021 - remaining	$ 982,387
2022 - 2025	115,000
Total Collaborative Agreement Obligations	$ 1,097,387

Commitments and Contingencies_8

Commitments and Contingencies (Details Narrative)	Nov. 03, 2020	Dec. 13, 2019USD ($)$ / sharesshares	Dec. 13, 2019EUR (€)shares	Mar. 31, 2021USD ($)	Mar. 31, 2021EUR (€)	Mar. 31, 2021EUR (€)	Dec. 31, 2020USD ($)
Total Long-Term Debt				$ 3,231,243
Payments for future research and collobration				1,100,000
Short term lease costs				15,647
Aggerate amount payable, description	the Company to pay in aggregate of up to $2.9 million over a period of 22 months.
Operating lease right-of-use assets				303,548			$ 326,085
Operating Lease Right of Use Obligations [Member]
Short term lease costs				$ 309,379
Weighted average discount rate				4.49%		4.49%
Weighted average remaining lease term				29 months	29 months
Operating lease right-of-use assets				$ 303,548
Payment of lease liabilities				21,562
Operating lease expense				21,488
Managing Director's Agreement [Member]
Amount payable				$ 229
Transaction agreement description				In connection with the transaction agreement, the Company also entered into a 2-year Managing Director’s agreement with the founder of Octamer to continue to manage Volition Germany for a payment of €288,000 payable in equal monthly installments over such 2-year period and a royalty agreement with the founder providing for the payment of royalties in the amount of 6% of net sales of Volition Germany’s nucleosomes as reagents to pharmaceutical companies for use in the development, manufacture and screening of molecules for use as therapeutic drugs for a period of 5 years post-closing.	In connection with the transaction agreement, the Company also entered into a 2-year Managing Director’s agreement with the founder of Octamer to continue to manage Volition Germany for a payment of €288,000 payable in equal monthly installments over such 2-year period and a royalty agreement with the founder providing for the payment of royalties in the amount of 6% of net sales of Volition Germany’s nucleosomes as reagents to pharmaceutical companies for use in the development, manufacture and screening of molecules for use as therapeutic drugs for a period of 5 years post-closing.
Royalty payment				$ 126,829
Royality				6.00%	6.00%
Stock based compensation expenses				$ 753,000
On September 16, 2020 [Member] | Bioinformatic Analytics Of Cell Free DNA [Member]
Total long-term debt				21,482
Repayment of long-term loan amount | €					€ 54,879
In 2019 [Member] | Taxes A&M University [Member]
Repayment of long-term loan amount				$ 400,000
Loan agreement term				5 years	5 years
Collaborative obligations amount due				$ 235,036
In 2018 [Member] | Long-term Debt [Member] | Loan Agreement [Member] | Namur Innovation and Growth [Member]
Total long-term debt				$ 219,184
Repayment of long-term loan amount | €					€ 500,000
Loan agreement term				4 years	4 years
Fixed interest rate				4.00%		4.00%
Maturity date				Jun. 30, 2022	Jun. 30, 2022
In 2018 [Member] | Finance Lease Obligations [Member] | BNP Paribas leasing solutions [Member]
Purchase price for the property | €						€ 25,000
Maturity date				Jan. 31, 2022	Jan. 31, 2022
Amount payable				$ 8,826
Implicit interest				1.35%		1.35%
Leased equipment amortized term				5 years	5 years
October 25, 2019 [Member] | TAMU [Member]
Non-controlling interest				7.50%	7.50%
Equity interest				12.50%	12.50%
Additional interest				5.00%	5.00%
January 10, 2020 [Member]
Common stock, restricted shares issued in exchange of purchased outstanding shares, value		$ 333,969
Restricted shares issued | shares		73,263	73,263
Common stock, restricted shares issued in exchange of purchased outstanding shares, shares | shares		73,263	73,263
Weighted trading price per share | $ / shares		$ 4.56
Repayment of debt | €			€ 350,000
Common stock adjusted amount		$ 357,000
Holdback period				9 months	9 months
Holdback liabilities				$ 55,404
Net liabilities		$ 43,152
In 2019 [Member] | Collaborative Arrangement, Co-promotion [Member]
Collaborative obligations amount due				$ 96,000
Research collaboration agreement description				The Company entered into a research collaboration agreement with the University of Taiwan to collect a total of 1,200 samples for a 2-year period for a cost to the Company of up to $320,000 payable over such period	The Company entered into a research collaboration agreement with the University of Taiwan to collect a total of 1,200 samples for a 2-year period for a cost to the Company of up to $320,000 payable over such period
ING [Member] | In 2016 [Member] | Long-term Debt [Member]
Fixed interest rate on lease				2.62%		2.62%
Lease payable				$ 612,599
Purchase price for the property | €						€ 1,120,000
ING [Member] | In 2016 [Member] | Long-term Debt [Member] | Loan Agreement [Member]
Total long-term debt				$ 240,838
Repayment of long-term loan amount | €					€ 270,000
Loan agreement term				15 years	15 years
Fixed interest rate				2.62%		2.62%
Maturity date				Dec. 31, 2031	Dec. 31, 2031
Namur [Member] | October 13, 2020 [Member] | Long-term Debt [Member] | Loan Agreement [Member]
Total long-term debt				$ 974,706
Borrowed amount | €					€ 65,453
Repayment of long-term loan amount | €					€ 830,000
Loan agreement term				10 years	10 years
Fixed interest rate				4.00%		4.00%
Maturity date				Mar. 31, 2021	Mar. 31, 2021
Namur Invest [Member] | In 2016 [Member] | Long-term Debt [Member] | Loan Agreement [Member]
Total long-term debt				$ 238,568
Repayment of long-term loan amount | €					€ 440,000
Loan agreement term				7 years	7 years
Fixed interest rate				4.85%		4.85%
Maturity date				Dec. 31, 2023	Dec. 31, 2023
Namur Invest [Member] | In 2019 [Member] | Long-term Debt [Member] | Loan Agreement [Member]
Total long-term debt				$ 587,171
Repayment of long-term loan amount | €					€ 500,000
Loan agreement term				4 years	4 years
Fixed interest rate				4.80%		4.80%
Maturity date				Sep. 30, 2024	Sep. 30, 2024
Namur Invest [Member] | In 2017 [Member] | Long-term Debt [Member] | Loan Agreement [Member]
Total long-term debt				$ 31,302
Repayment of long-term loan amount | €					€ 350,000
Loan agreement term				4 years	4 years
Fixed interest rate				4.00%		4.00%
Maturity date				Jun. 30, 2021	Jun. 30, 2021
SOFINEX [Member] | In 2017 [Member] | Long-term Debt [Member] | Loan Agreement [Member]
Total long-term debt				$ 939,474
Repayment of long-term loan amount | €					€ 1,000,000
Loan agreement term				7 years	7 years
Fixed interest rate				4.50%		4.50%
Maturity date				Sep. 30, 2024	Sep. 30, 2024
Walloon Region Government [Member] | In 2010 [Member]
Repayment of long-term loan amount | €					€ 315,788
Amount payable				$ 102,645
Grant receivable | €						€ 1,050,000
Repayment of grants | €						314,406
Terms of agreement description				it is due to pay a 6% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €314,406 and the 6% royalty on revenue, is equal to twice the amount of funding received.	it is due to pay a 6% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €314,406 and the 6% royalty on revenue, is equal to twice the amount of funding received.
Walloon Region Government [Member] | In 2018 [Member] | Colorectal Cancer Research Agreement [Member]
Amount payable				$ 213,143
Grant receivable | €						605,000
Repayment of grants | €						181,500
Terms of agreement description				It is due to pay a 3.53% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €181,500 and the 3.53% royalty on revenue, is equal to the amount of funding received.	It is due to pay a 3.53% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of €181,500 and the 3.53% royalty on revenue, is equal to the amount of funding received.
DKFZ [Member] | In 2016 [Member] | Research Co-operation Agreement [Member]
Collaborative obligations amount due				$ 234,869
Lease agreement expire period				5 years	5 years
Collaborative obligations amount | €						€ 400,000
University of Taiwan [Member] | In 2018 [Member] | Clinical Study Research Agreement [Member]
Collaborative obligations amount due				$ 510,000
Lease agreement expire period				3 years	3 years
Collaborative obligations amount				$ 2,550,000

Subsequent (Details Narrative)

Subsequent (Details Narrative) - USD ($)	Apr. 13, 2021	Mar. 31, 2021	Dec. 31, 2020
Common stock shares issued		52,871,001	48,607,017
Subsequent Event [Member]
RSUs granted upon common shares	20,625
Restricted stock units price per share	$ 3.44
Common stock shares issued	16,087
Subsequent Event [Member] | Restricted Stock Units [Member]
RSUs granted upon common shares	5,625
Restricted stock units price per share	$ 3.44
Common stock shares issued	5,625
May 1, 2021 [Member]
RSU term descriptions		These RSUs vest as follows one-third after 12 months, one-third after 24 months, and the remaining one-third after 36 months and will result in total compensation expense of $496,500.
Total Compensation expense		$ 496,500
RSUs granted upon common shares		150,000